ClinicalTrials.gg
CompletedNCT05834868Updated Dec 22, 2025

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

A Phase 3 interventional study of THDB0206 Injection and Insulin Lispro Injection in Type 2 Diabetes, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled May 2022, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,040
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
72nd of 767
1,040 · median 199
Started
2022
with 65 others
Phase 3
207 of 909
38 open now
Registered
584th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 72nd largest by enrollment of the 767 interventional ones that give a count, is one of 66 that started in 2022, is one of 207 in phase 3, and was the 584th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T2DM.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : 18.0 kg/m\^2\~35.0 kg/m\^2 (both inclusive) at the time of screening.
  • : 7.0%\~10.0% (both inclusive) at the time of screening.
  • Diagnosed with T2DM for 6 months or longer at the time of screening based on the World Health Organization (WHO) classification.
  • Treated with stable insulin regimen as follow for at least 3 months with or without oral antidiabetic drug:

    1. Basal insulin (neutral protamine Hagedorn [NPH] insulin, insulin glargine, insulin degludec, insulin detemir) in combination with at least 1 prandial injection of bolus insulin.
    2. Premixed insulin at least twice daily.

Exclusion criteria

Exclusion Criteria:

  • Have other types of diabetes other than T2DM.
  • Have used Glucagon-Like Peptide 1 (GLP-1) receptor agonist within 3 months prior to screening.
  • Have had 1 or more episodes of severe hypoglycemia within the 6 months prior to screening.
  • Have had 1 or more episodes of acute diabetic complications (diabetic ketoacidosis, hyperglycemic hyperosmolar state, diabetic lactic acidosis, etc.) within the 6 months prior to screening.
  • With concomitant conditions at screening that may affect the evaluation of the study, including cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, liver diseases, kidney diseases, nervous system diseases, psychiatric diseases, hematological diseases, immune system diseases, endocrine system diseases, pancreatic diseases, and/or malignant tumors.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,040 participants (actual)

Study arms

  • Experimental
    THDB0206 Injection

    Drug: THDB0206 Injection

  • Active comparator
    Insulin Lispro Injection

    Drug: Insulin Lispro Injection

Interventions

  • Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.

  • Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.

06

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment

    Time frame: Week 26

Secondary outcomes

  1. Change From Baseline in 1-hour Postprandial Glucose (PPG) Excursion at Week 26

    Time frame: Week 26

  2. Change From Baseline in 2-hour Postprandial Glucose (PPG) Excursion at Week 26

    Time frame: Week 26

07

Study locations

1 site
  • Zhongshan Hospital
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2024, 31 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 31 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2023
First posted
Apr 28, 2023
StartActual
May 6, 2022
Primary completionActual
Dec 10, 2024
CompletionActual
Dec 31, 2024
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05834868
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Apr 28, 2023
Start date
May 6, 2022
Primary completion
Dec 10, 2024
Completion
Dec 31, 2024
Last update
Dec 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THDB0206

Start the discussion